Wolf–Hirschhorn syndrome (WHS): Disease Characteristics Research Report

Target disease: Wolf–Hirschhorn syndrome (genetic contiguous gene deletion disorder; distal 4p deletion). (nevado2020internationalmeetingon pages 3-4, zollino2008onthenosology pages 1-2)

Executive summary (current understanding)

Wolf–Hirschhorn syndrome (WHS) is a contiguous gene deletion syndrome caused by loss of genetic material from the distal short arm of chromosome 4 (4p16.3). It is clinically characterized by a recognizable core phenotype comprising typical craniofacial dysmorphism (“Greek warrior helmet” gestalt), prenatal/postnatal growth deficiency, developmental delay/intellectual disability, and seizures/EEG abnormalities. (nevado2020internationalmeetingon pages 3-4, berrocoso2020copingwithwolfhirschhorna pages 1-2, zollino2008onthenosology pages 1-2)

Recent large-cohort work (Spain/Latin America, n=140; collected 2013–2023) underscores that epilepsy is highly prevalent (92%), begins in infancy (mean onset ~9.8 months), and is frequently severe (status epilepticus 58.4%), with substantial treatment burden (polytherapy common). (blancolago2025epilepsyinwolf–hirschhorn pages 2-4, blancolago2025epilepsyinwolf–hirschhorn pages 1-2)

A major mechanistic advance over the last decade is the refinement of a terminal 4p seizure susceptibility region to an ~197 kb interval near the telomere (hg19/GRCh37 chr4:367,691–564,593), containing PIGG and ZNF721 (and ABCA11P), suggesting that seizure risk is driven by haploinsufficiency of telomeric genes beyond the historically emphasized LETM1 region in at least some individuals. (ho2016chromosomalmicroarraytesting pages 1-1, ho2016chromosomalmicroarraytesting media f15f4c0a)

1. Disease information

1.1 Definition/overview

WHS is a chromosomal disorder caused by distal 4p deletions (usually 4p16.3), producing a multisystem developmental syndrome with characteristic facial features, growth delay, intellectual disability/developmental delay, and seizures. (nevado2020internationalmeetingon pages 3-4, zollino2008onthenosology pages 1-2)

1.2 Key identifiers

• OMIM: #194190 (explicitly stated in WHS nosology/meeting proceedings). (nevado2020internationalmeetingon pages 2-2)
• MONDO / MeSH / ICD-10 / ICD-11 / Orphanet ORPHAcode: Not retrievable from the tool-accessible full-text corpus in this run. (see Limitations).

1.3 Common synonyms / alternative names

• “4p- syndrome”, “deletion 4p”, “terminal 4p deletion” (terminology used across prenatal and clinical genetics literature). (sifakis2012prenataldiagnosisof pages 1-2, nevado2020internationalmeetingon pages 3-4)

1.4 Source type (individual vs aggregated)

Evidence in this report derives from: - Aggregated cohorts and registries (e.g., epidemiology cohort n=159; epilepsy cohort n=140; prenatal cohort n=18). (shannon2001anepidemiologicalstudy pages 1-2, blancolago2025epilepsyinwolf–hirschhorn pages 2-4, simonini2022prenatalsonographicfindings pages 1-2) - Curated clinical genetics guidance (clinical utility gene card). (battaglia2011clinicalutilitygene pages 1-2) - Model organism and developmental biology studies/reviews supporting mechanistic hypotheses. (, )

2. Etiology

2.1 Disease causal factors

Primary cause: hemizygous deletion of the distal short arm of chromosome 4 (4p16.3), with variable deletion size and complexity, producing a contiguous gene haploinsufficiency syndrome. (zollino2008onthenosology pages 1-2, nevado2020internationalmeetingon pages 3-4)

Rearrangement classes reported include: - terminal deletions (most common), - interstitial 4p deletions, - unbalanced translocations (including recurrent 4p;8p events), - ring chromosome 4, - inverted duplications/complex rearrangements. (ho2016chromosomalmicroarraytesting pages 1-1, nevado2020internationalmeetingon pages 4-4, simonini2022prenatalsonographicfindings pages 5-7)

2.2 Risk factors

Genetic risk factors: Presence of a parental balanced translocation involving 4p can raise recurrence risk for offspring with an unbalanced rearrangement; thus parental cytogenetic testing is relevant for counseling. (simonini2022prenatalsonographicfindings pages 5-7, xing2018prenataldiagnosisof pages 5-7)

Environmental risk factors: Not supported in the retrieved evidence; WHS is primarily genetic due to structural chromosome abnormalities. (nevado2020internationalmeetingon pages 3-4, zollino2008onthenosology pages 1-2)

2.3 Protective factors

No validated genetic or environmental protective factors were identified in the retrieved literature.

2.4 Gene–environment interactions

No WHS-specific gene–environment interactions were identified in the retrieved literature.

3. Phenotypes (clinical spectrum)

3.1 Core phenotype (postnatal)

The consensus “core WHS phenotype” includes typical facial dysmorphism, growth delay, intellectual disability/developmental delay, and seizures (or EEG abnormalities). (nevado2020internationalmeetingon pages 3-4)

A large cohort (n=140) quantified high frequencies of major features: - Psychomotor developmental delay: ~98.9% - Craniofacial features: ~97.8% - Hypotonia: ~89% - IUGR/postnatal growth restriction: ~94.2% - Cardiac defects: ~44.5% - Renal/urological anomalies: ~53% (these are cohort-derived rates reported in the epilepsy-focused cohort paper). (blancolago2025epilepsyinwolf–hirschhorn pages 1-2)

3.2 Epilepsy phenotype (key quantitative data)

In the same n=140 cohort, epilepsy burden was high and early-onset: - Epilepsy prevalence: 92% (126/137) - Mean seizure onset: 9.8 months (range 3 days–36 months) - Seizure types (proportions): generalized tonic-clonic 55.9%, absence/atypical absence 51.8%, focal 26.9%, tonic 24.3%, myoclonic 20.4%, epileptic spasms 12.4% - Status epilepticus: 58.4% - Febrile-triggered seizures: 68.6% - Treatment burden: 85.9% treated with antiseizure medications; 42.2% had used ≥3 ASMs; commonly used ASMs were valproic acid and levetiracetam - Genotype–phenotype: larger deletions (>9 Mb) associated with more severe epilepsy and poorer developmental outcomes (pediatric cohort with standardized caregiver questionnaires). (blancolago2025epilepsyinwolf–hirschhorn pages 2-4, blancolago2025epilepsyinwolf–hirschhorn pages 1-2)

Suggested HPO terms (examples): - Seizures HP:0001250; Epileptic spasms HP:0011097; Status epilepticus HP:0002133; Febrile seizures HP:0002373; Developmental delay HP:0001263; Intellectual disability HP:0001249; Hypotonia HP:0001252; Intrauterine growth restriction HP:0001511; Failure to thrive HP:0001508; Microcephaly HP:0000252; Congenital heart defect HP:0001627; Renal anomaly HP:0000077.

3.3 Prenatal phenotype (ultrasound; frequencies)

In a retrospective prenatal cohort of 18 confirmed WHS cases (3 tertiary centers in Germany), the most frequent ultrasound findings were: - Facial abnormalities: 94.4% (17/18) - Symmetric IUGR: 83.3% (15/18) - Microcephaly: 72.2% (13/18) - Cardiac anomalies: 50.0% (9/18) A particularly characteristic combination was microcephaly + hypoplastic nasal bone; growth restriction was present in all fetuses assessed after 20 weeks. (simonini2022prenatalsonographicfindings pages 1-2, simonini2022prenatalsonographicfindings pages 5-7)

A broader prenatal review (10 new + 37 literature cases) reported severe IUGR 97.7% and typical facial appearance 82.9%, with cardiac malformations 29.8% and renal hypoplasia 36.2%. (xing2018prenataldiagnosisof pages 1-2)

Suggested prenatal HPO terms (examples): IUGR HP:0001511; Hypoplastic nasal bone HP:0012745; Abnormal facial shape HP:0001999; Micrognathia HP:0000347.

3.4 Quality of life impact

A study of 22 Spanish caregivers evaluated psychosocial profile and caregiver quality of life (QoL) and found that the syndrome’s severe, lifelong care needs (growth issues, seizures, developmental disability) can impact parental QoL; problem-focused coping and social support were associated with improved psychological QoL. (berrocoso2020copingwithwolfhirschhorna pages 1-2)

4. Genetic / molecular information

4.1 Causal genomic lesion and critical regions

WHS is caused by deletions of 4p16.3 with broad size variation; meeting proceedings and genotype–phenotype analyses emphasize variability from <2 Mb up to ~30 Mb or more. (nevado2020internationalmeetingon pages 3-4)

Historically defined WHS “critical regions” include: - WHSCR: a ~165 kb interval ~2 Mb from the telomere, containing WHSC1/NSD2 and WHSC2/NELFA. (nevado2020internationalmeetingon pages 4-4) - WHSCR-2: an adjacent 300–600 kb interval including LETM1 (a long-discussed seizure candidate) and part of WHSC1/NSD2. (ho2016chromosomalmicroarraytesting pages 1-1)

4.2 Genotype–phenotype correlations (deletion size)

Multiple sources define broad severity bands: - Mild: deletions ≤3.5 Mb - Typical/classic: ~5–18 Mb - Severe: ~22–25 Mb or more (Prenatal and postnatal sources concordantly report this pattern). (zollino2008onthenosology pages 1-2, luo2023prenataldiagnosisand pages 2-3, simonini2022prenatalsonographicfindings pages 5-7)

4.3 Seizure susceptibility region (recent mapping)

A chromosomal microarray mapping study (n=48) identified a strong association between interstitial deletions that exclude the distal terminal segment and absence of seizures, and refined a terminal seizure susceptibility region to ~197 kb beginning ~368 kb from the 4p terminus. (ho2016chromosomalmicroarraytesting pages 1-1)

Figure-based coordinates and genes in this interval (hg19/GRCh37 chr4:367,691–564,593) include PIGG and ZNF721 (and ABCA11P). (ho2016chromosomalmicroarraytesting media f15f4c0a)

4.4 Inheritance and origin

WHS rearrangements are often de novo, but familial recurrence can occur via parental balanced translocations. In a UK epidemiologic cohort (n=159): 72.3% de novo deletions, 20.1% translocations, 7.5% other rearrangements. (shannon2001anepidemiologicalstudy pages 1-2)

In the prenatal literature, approximate etiologic fractions are described as ~55% de novo deletions, ~40–45% unbalanced translocations, and ~5% complex rearrangements. (simonini2022prenatalsonographicfindings pages 5-7)

4.5 Epigenetics / modifiers

Phenotypic severity is not strictly linear with deletion size; meeting proceedings discuss that LETM1 haploinsufficiency alone is not sufficient for seizures, implying additional telomeric dosage-sensitive genes and/or modifier effects. (nevado2020internationalmeetingon pages 4-5)

5. Environmental information

No WHS-specific environmental toxins, lifestyle risk factors, or infectious triggers causing WHS were identified in retrieved evidence. WHS is primarily a structural genomic disorder. (nevado2020internationalmeetingon pages 3-4, zollino2008onthenosology pages 1-2)

6. Mechanism / pathophysiology

6.1 Causal chain (conceptual)

Upstream trigger: hemizygous deletion of distal 4p (4p16.3) → haploinsufficiency of multiple developmental genes (including NSD2/WHSC1, NELFA/WHSC2, LETM1, and telomeric genes such as PIGG/ZNF721) → disruption of transcriptional regulation, neuronal excitability balance and developmental programs → downstream neurodevelopmental impairment, growth delay, craniofacial malformations, congenital anomalies, and epilepsy (often early-onset and severe). (zollino2008onthenosology pages 1-2, ho2016chromosomalmicroarraytesting pages 1-1, nevado2020internationalmeetingon pages 4-5)

6.2 Seizure biology (regional genetics)

The CMA mapping work supports a model in which deletion of a small terminal region can be sufficient for seizure susceptibility in WHS, refining the mechanistic focus beyond LETM1 alone. (ho2016chromosomalmicroarraytesting pages 1-1, ho2016chromosomalmicroarraytesting media f15f4c0a)

6.3 Developmental mechanisms: neural crest hypothesis (model-organism evidence)

A Xenopus-focused primary study supports the hypothesis that WHS craniofacial and related defects may arise from perturbation of cranial neural crest biology: WHS-associated genes (whsc1, whsc2, letm1, tacc3) show enrichment in migratory neural crest and influence craniofacial patterning/cartilage formation and neural crest motility when depleted. ()

Suggested GO Biological Process terms (examples): - cranial neural crest cell migration (GO:0002302), - regulation of transcription, DNA-templated (GO:0006355), - nervous system development (GO:0007399), - synaptic signaling (GO:0099536), - mitochondrial calcium ion homeostasis (candidate for LETM1-related mechanisms).

Suggested CL cell-type terms (examples): - neural crest cell (CL:0000134), - excitatory neuron (CL:0000127), - inhibitory interneuron (CL:0000099).

7. Anatomical structures affected

Based on the multisystem phenotype described in cohorts: - Nervous system: epilepsy, developmental delay (UBERON:0001016 “nervous system”; brain UBERON:0000955). (blancolago2025epilepsyinwolf–hirschhorn pages 2-4) - Craniofacial structures: characteristic facial gestalt; craniofacial developmental defects (UBERON:0001136 “facial skeleton”). (berrocoso2020copingwithwolfhirschhorna pages 1-2) - Cardiovascular system: congenital heart defects (~44.5% in a large cohort; 50% in prenatal series). (blancolago2025epilepsyinwolf–hirschhorn pages 1-2, simonini2022prenatalsonographicfindings pages 1-2) - Urinary system/kidney: renal/urologic anomalies (~53% in large cohort; renal hypoplasia often reported prenatally). (blancolago2025epilepsyinwolf–hirschhorn pages 1-2, xing2018prenataldiagnosisof pages 1-2)

8. Temporal development

• Onset: congenital; many features are prenatal (IUGR, microcephaly, facial anomalies) and postnatal developmental delay is universal/near-universal in cohorts. (simonini2022prenatalsonographicfindings pages 1-2, blancolago2025epilepsyinwolf–hirschhorn pages 1-2)
• Epilepsy onset: typically within the first year; mean onset ~9.8 months. (blancolago2025epilepsyinwolf–hirschhorn pages 2-4)
• Course: high early-childhood morbidity and mortality; survival improves after age 2, with some individuals surviving into adulthood (documented up to mid-30s in UK cohort, and to 55 years in adult natural history series). (shannon2001anepidemiologicalstudy pages 1-2, shannon2001anepidemiologicalstudy pages 1-1)

9. Inheritance and population

9.1 Epidemiology

• Minimum UK birth incidence (1989–1998): 1 in 95,896. (shannon2001anepidemiologicalstudy pages 1-2, shannon2001anepidemiologicalstudy pages 1-1)
• Commonly cited incidence/prevalence in clinical literature: ~1/20,000–1/50,000 births, with female predominance ~2:1. (berrocoso2020copingwithwolfhirschhorna pages 1-2, nevado2025clinicianbasedfunctionalscoring pages 1-2)

9.2 Inheritance pattern

WHS is typically sporadic/de novo as a chromosomal deletion syndrome; familial recurrence risk depends on parental chromosomal rearrangements (balanced translocation carriers). (shannon2001anepidemiologicalstudy pages 1-2, simonini2022prenatalsonographicfindings pages 5-7)

10. Diagnostics

10.1 Clinical suspicion

• Prenatal: symmetric IUGR + microcephaly + hypoplastic nasal bone + facial anomalies should raise suspicion. (simonini2022prenatalsonographicfindings pages 1-2)
• Postnatal: characteristic facial gestalt + growth restriction + neurodevelopmental delay + seizures/EEG abnormalities. (nevado2020internationalmeetingon pages 3-4, berrocoso2020copingwithwolfhirschhorna pages 1-2)

10.2 Genetic testing strategy (real-world implementation)

• Chromosomal microarray (CMA) is highlighted as the method of choice for diagnosis, particularly to detect small deletions (<3 Mb) and complex rearrangements. (simonini2022prenatalsonographicfindings pages 1-2, simonini2022prenatalsonographicfindings pages 5-7)
• Routine karyotype detection ~50–60%; FISH sensitivity ~95% in prenatal review. (simonini2022prenatalsonographicfindings pages 1-2)
• Clinical utility gene card: appropriately designed FISH or genomic microarray targeting at least portions of LETM1 and WHSC1 should yield >99% clinical sensitivity; standard chromosome studies may have only ~50–60% sensitivity and can miss microdeletions. (battaglia2011clinicalutilitygene pages 1-2)

10.3 Differential diagnosis

A formal differential diagnosis list was not available in retrieved full texts. In practice, WHS overlaps with other chromosomal deletion syndromes presenting with growth restriction, dysmorphism, and epilepsy; confirmation requires molecular cytogenetics (CMA/FISH/karyotype). (battaglia2011clinicalutilitygene pages 1-2, nevado2020internationalmeetingon pages 3-4)

11. Outcomes / prognosis

11.1 Survival and mortality (key statistics)

In the UK epidemiologic cohort: - Infant mortality: 17.4% (23/132) - Two-year mortality: 21% (28/132) - Timing: 63.9% of deaths in the first year; 77.8% within the first two years - Deletion size prognostic factor: large deletions had 51.5% deaths vs 9.7% for small deletions; adjusted OR 5.7 (95% CI 1.7–19.9) (published Oct 2001). (shannon2001anepidemiologicalstudy pages 3-4)

Among deaths with known cause (n=32): - lower respiratory tract infection 25% (8/32), - multiple congenital anomalies 15.6% (5/32), - sudden unexplained death 15.6% (5/32), - congenital heart disease 15.6% (5/32). (published Oct 2001). (shannon2001anepidemiologicalstudy pages 4-5)

11.2 Prognostic factors

• Deletion size and complexity (large deletions, complex rearrangements). (shannon2001anepidemiologicalstudy pages 3-4)
• Epilepsy severity and seizure pattern, emphasized as major determinants of neurodevelopmental outcome. (nevado2020internationalmeetingon pages 3-4, blancolago2025epilepsyinwolf–hirschhorn pages 2-4)

12. Treatment

12.1 Pharmacotherapy (epilepsy)

In a large WHS cohort, commonly used antiseizure medications were valproic acid and levetiracetam, and many individuals required polytherapy; status epilepticus was frequent and likely contributes to developmental burden. (blancolago2025epilepsyinwolf–hirschhorn pages 1-2, blancolago2025epilepsyinwolf–hirschhorn pages 2-4)

Suggested MAXO terms (examples): - antiseizure therapy (MAXO:0000474), - status epilepticus management (MAXO term to map under emergency seizure management), - chromosomal microarray analysis (diagnostic procedure term), - genetic counseling (MAXO:0000072), - early intervention therapy / neurodevelopmental therapy (MAXO mapping under rehabilitation).

12.2 Supportive / rehabilitative care

Consensus and cohort interpretations emphasize multidisciplinary management (developmental therapies, monitoring for comorbidities such as cardiac/renal problems, and family support). (berrocoso2020copingwithwolfhirschhorna pages 1-2, shannon2001anepidemiologicalstudy pages 6-6)

12.3 Experimental / trials

A precise ClinicalTrials.gov condition search for “Wolf-Hirschhorn syndrome” did not retrieve disease-specific interventional trials in this tool run; earlier broad “WHS” queries primarily matched unrelated acronym uses (e.g., Women’s Health Study). (nevado2020internationalmeetingon pages 11-11)

13. Prevention

Primary “prevention” for WHS is reproductive/genetic: - Genetic counseling for affected families, - Prenatal diagnosis using ultrasound plus confirmatory CMA/karyotype/FISH, - Parental karyotyping to detect balanced translocations that elevate recurrence risk. (simonini2022prenatalsonographicfindings pages 5-7, battaglia2011clinicalutilitygene pages 1-2)

14. Other species / natural disease

No naturally occurring veterinary analogs were identified in retrieved evidence.

15. Model organisms

Mechanistic studies in vertebrate models support developmental hypotheses: - Xenopus laevis: WHS-associated genes are enriched in migratory neural crest cells; depletion affects craniofacial development and neural crest motility. () - Additional vertebrate resources were retrieved for zebrafish WHSC1/NSD2 homolog biology, supporting in vivo functional studies of WHS candidate genes. ()

Recent developments (prioritizing 2023–2024 where available)

• 2024: A familial terminal 4p16.3 microdeletion not causing classical WHS supports refinement of critical regions and highlights interpretive complexity for small telomeric CNVs. (Osundiji 2024; publication date Nov 2024; Chromosome Research). (osundiji2024afamilialchromosome pages 7-8)
• 2024: Basic mechanistic enzymology work expanded the substrate landscape of NSD2 (WHSC1), relevant to understanding pleiotropy of NSD2 haploinsufficiency in development and disease (not WHS-specific clinical study, but mechanistically relevant). (Weirich 2024; Communications Biology; Jun 2024). ()

Key quantitative findings (quick reference)

Table: This table compiles the most implementation-relevant quantitative findings for Wolf-Hirschhorn syndrome, including epidemiology, mortality, epilepsy burden, prenatal detection, testing performance, and the mapped seizure-susceptibility region. It is designed for quick reference in clinical or knowledge-base curation workflows.

Visual evidence (genotype–seizure mapping)

The seizure susceptibility region on terminal 4p and the gene content of the refined ~197 kb interval are illustrated in the CMA mapping figures (Figure 2/3) from Ho et al. 2016. (ho2016chromosomalmicroarraytesting media 365127d8, ho2016chromosomalmicroarraytesting media f15f4c0a)

Limitations of this report (tooling constraints)

• The tool-accessible corpus did not yield primary sources explicitly listing MONDO ID, Orphanet ORPHAcode, MeSH descriptor ID, or ICD-10/ICD-11 codes for WHS; therefore these identifiers are not asserted here.
• Several clinically important areas (formal differential diagnosis lists; standardized QoL instruments for affected individuals) were not available in retrieved texts and may require additional targeted retrieval beyond the current run.

References

1. (nevado2020internationalmeetingon pages 3-4): Julián Nevado, Karen S. Ho, Marcella Zollino, Raquel Blanco, César Cobaleda, Christelle Golzio, Isabelle Beaudry‐Bellefeuille, Sarah Berrocoso, Jacobo Limeres, Pilar Barrúz, Candela Serrano‐Martín, Concetta Cafiero, Ignacio Málaga, Giuseppe Marangi, Elena Campos‐Sánchez, Tania Moriyón‐Iglesias, Sorangui Márquez, Leah Markham, Hope Twede, Amanda Lortz, Lenora Olson, Xiaoming Sheng, Cindy Weng, Edward Robert Wassman, Tara Newcomb, Edward Robert Wassman, John C. Carey, Agatino Battaglia, Eduardo López‐Granados, Damien Douglas, and Pablo Lapunzina. International meeting on wolf‐hirschhorn syndrome: update on the nosology and new insights on the pathogenic mechanisms for seizures and growth delay. American Journal of Medical Genetics Part A, 182:257-267, Nov 2020. URL: https://doi.org/10.1002/ajmg.a.61406, doi:10.1002/ajmg.a.61406. This article has 31 citations.

2. (zollino2008onthenosology pages 1-2): Marcella Zollino, Marina Murdolo, Giuseppe Marangi, Vanna Pecile, Cinzia Galasso, Laura Mazzanti, and Giovanni Neri. On the nosology and pathogenesis of wolf–hirschhorn syndrome: genotype–phenotype correlation analysis of 80 patients and literature review. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 148C:257-269, Nov 2008. URL: https://doi.org/10.1002/ajmg.c.30190, doi:10.1002/ajmg.c.30190. This article has 216 citations.

3. (berrocoso2020copingwithwolfhirschhorna pages 1-2): Sarah Berrocoso, Imanol Amayra, Esther Lázaro, Oscar Martínez, Juan Francisco López-Paz, Maitane García, Manuel Pérez, Mohammad Al-Rashaida, Alicia Aurora Rodríguez, Paula Maria Luna, Paula Pérez-Núñez, Raquel Blanco, and Julián Nevado. Coping with wolf-hirschhorn syndrome: quality of life and psychosocial features of family carers. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01476-8, doi:10.1186/s13023-020-01476-8. This article has 29 citations and is from a peer-reviewed journal.

4. (blancolago2025epilepsyinwolf–hirschhorn pages 2-4): Raquel Blanco-Lago, Ignacio Málaga, Jair Antonio Tenorio-Castaño, Nelly Álvarez-Álvarez, Pablo Lapunzina, and Julián Nevado. Epilepsy in wolf–hirschhorn syndrome: clinical insights from a pediatric cohort and a review of the literature. Journal of Clinical Medicine, 14:8044, Nov 2025. URL: https://doi.org/10.3390/jcm14228044, doi:10.3390/jcm14228044. This article has 0 citations.

5. (blancolago2025epilepsyinwolf–hirschhorn pages 1-2): Raquel Blanco-Lago, Ignacio Málaga, Jair Antonio Tenorio-Castaño, Nelly Álvarez-Álvarez, Pablo Lapunzina, and Julián Nevado. Epilepsy in wolf–hirschhorn syndrome: clinical insights from a pediatric cohort and a review of the literature. Journal of Clinical Medicine, 14:8044, Nov 2025. URL: https://doi.org/10.3390/jcm14228044, doi:10.3390/jcm14228044. This article has 0 citations.

6. (ho2016chromosomalmicroarraytesting pages 1-1): Karen S Ho, Sarah T South, Amanda Lortz, Charles H Hensel, Mallory R Sdano, Rena J Vanzo, Megan M Martin, Andreas Peiffer, Christophe G Lambert, Amy Calhoun, John C Carey, and Agatino Battaglia. Chromosomal microarray testing identifies a 4p terminal region associated with seizures in wolf–hirschhorn syndrome. Journal of Medical Genetics, 53:256-263, Jan 2016. URL: https://doi.org/10.1136/jmedgenet-2015-103626, doi:10.1136/jmedgenet-2015-103626. This article has 59 citations and is from a domain leading peer-reviewed journal.

7. (ho2016chromosomalmicroarraytesting media f15f4c0a): Karen S Ho, Sarah T South, Amanda Lortz, Charles H Hensel, Mallory R Sdano, Rena J Vanzo, Megan M Martin, Andreas Peiffer, Christophe G Lambert, Amy Calhoun, John C Carey, and Agatino Battaglia. Chromosomal microarray testing identifies a 4p terminal region associated with seizures in wolf–hirschhorn syndrome. Journal of Medical Genetics, 53:256-263, Jan 2016. URL: https://doi.org/10.1136/jmedgenet-2015-103626, doi:10.1136/jmedgenet-2015-103626. This article has 59 citations and is from a domain leading peer-reviewed journal.

8. (nevado2020internationalmeetingon pages 2-2): Julián Nevado, Karen S. Ho, Marcella Zollino, Raquel Blanco, César Cobaleda, Christelle Golzio, Isabelle Beaudry‐Bellefeuille, Sarah Berrocoso, Jacobo Limeres, Pilar Barrúz, Candela Serrano‐Martín, Concetta Cafiero, Ignacio Málaga, Giuseppe Marangi, Elena Campos‐Sánchez, Tania Moriyón‐Iglesias, Sorangui Márquez, Leah Markham, Hope Twede, Amanda Lortz, Lenora Olson, Xiaoming Sheng, Cindy Weng, Edward Robert Wassman, Tara Newcomb, Edward Robert Wassman, John C. Carey, Agatino Battaglia, Eduardo López‐Granados, Damien Douglas, and Pablo Lapunzina. International meeting on wolf‐hirschhorn syndrome: update on the nosology and new insights on the pathogenic mechanisms for seizures and growth delay. American Journal of Medical Genetics Part A, 182:257-267, Nov 2020. URL: https://doi.org/10.1002/ajmg.a.61406, doi:10.1002/ajmg.a.61406. This article has 31 citations.

9. (sifakis2012prenataldiagnosisof pages 1-2): Stavros Sifakis, Emmanouil Manolakos, Annalisa Vetro, Dimitra Kappou, Panagiotis Peitsidis, Maria Kontodiou, Antonios Garas, Nikolaos Vrachnis, Anastasia Konstandinidou, Orsetta Zuffardi, Sandro Orru, and Ioannis Papoulidis. Prenatal diagnosis of wolf-hirschhorn syndrome confirmed by comparative genomic hybridization array: report of two cases and review of the literature. Molecular Cytogenetics, 5:12-12, Feb 2012. URL: https://doi.org/10.1186/1755-8166-5-12, doi:10.1186/1755-8166-5-12. This article has 35 citations and is from a peer-reviewed journal.

10. (shannon2001anepidemiologicalstudy pages 1-2): N. Shannon, E. Maltby, A. Rigby, and O. Quarrell. An epidemiological study of wolf-hirschhorn syndrome: life expectancy and cause of mortality. Journal of Medical Genetics, 38:674-679, Oct 2001. URL: https://doi.org/10.1136/jmg.38.10.674, doi:10.1136/jmg.38.10.674. This article has 138 citations and is from a domain leading peer-reviewed journal.

11. (simonini2022prenatalsonographicfindings pages 1-2): Corinna Simonini, Markus Hoopmann, Karl Oliver Kagan, Torsten Schröder, Ulrich Gembruch, and Annegret Geipel. Prenatal sonographic findings in confirmed cases of wolf-hirschhorn syndrome. BMC Pregnancy and Childbirth, Apr 2022. URL: https://doi.org/10.1186/s12884-022-04665-4, doi:10.1186/s12884-022-04665-4. This article has 13 citations and is from a peer-reviewed journal.

12. (battaglia2011clinicalutilitygene pages 1-2): Agatino Battaglia, Sarah South, and John C Carey. Clinical utility gene card for: wolf–hirschhorn (4p-) syndrome. European Journal of Human Genetics, 19:-, Apr 2011. URL: https://doi.org/10.1038/ejhg.2010.186, doi:10.1038/ejhg.2010.186. This article has 23 citations and is from a domain leading peer-reviewed journal.

13. (nevado2020internationalmeetingon pages 4-4): Julián Nevado, Karen S. Ho, Marcella Zollino, Raquel Blanco, César Cobaleda, Christelle Golzio, Isabelle Beaudry‐Bellefeuille, Sarah Berrocoso, Jacobo Limeres, Pilar Barrúz, Candela Serrano‐Martín, Concetta Cafiero, Ignacio Málaga, Giuseppe Marangi, Elena Campos‐Sánchez, Tania Moriyón‐Iglesias, Sorangui Márquez, Leah Markham, Hope Twede, Amanda Lortz, Lenora Olson, Xiaoming Sheng, Cindy Weng, Edward Robert Wassman, Tara Newcomb, Edward Robert Wassman, John C. Carey, Agatino Battaglia, Eduardo López‐Granados, Damien Douglas, and Pablo Lapunzina. International meeting on wolf‐hirschhorn syndrome: update on the nosology and new insights on the pathogenic mechanisms for seizures and growth delay. American Journal of Medical Genetics Part A, 182:257-267, Nov 2020. URL: https://doi.org/10.1002/ajmg.a.61406, doi:10.1002/ajmg.a.61406. This article has 31 citations.

14. (simonini2022prenatalsonographicfindings pages 5-7): Corinna Simonini, Markus Hoopmann, Karl Oliver Kagan, Torsten Schröder, Ulrich Gembruch, and Annegret Geipel. Prenatal sonographic findings in confirmed cases of wolf-hirschhorn syndrome. BMC Pregnancy and Childbirth, Apr 2022. URL: https://doi.org/10.1186/s12884-022-04665-4, doi:10.1186/s12884-022-04665-4. This article has 13 citations and is from a peer-reviewed journal.

15. (xing2018prenataldiagnosisof pages 5-7): Ya Xing, Jimmy Lloyd Holder, Yong Liu, Meizhen Yuan, Qi Sun, Xiaoxing Qu, Linbei Deng, Jia Zhou, Yingjun Yang, Ming Guo, Sau-Wai Cheung, and Luming Sun. Prenatal diagnosis of wolf–hirschhorn syndrome: from ultrasound findings, diagnostic technology to genetic counseling. Archives of Gynecology and Obstetrics, 298:289-295, May 2018. URL: https://doi.org/10.1007/s00404-018-4798-1, doi:10.1007/s00404-018-4798-1. This article has 36 citations and is from a peer-reviewed journal.

16. (xing2018prenataldiagnosisof pages 1-2): Ya Xing, Jimmy Lloyd Holder, Yong Liu, Meizhen Yuan, Qi Sun, Xiaoxing Qu, Linbei Deng, Jia Zhou, Yingjun Yang, Ming Guo, Sau-Wai Cheung, and Luming Sun. Prenatal diagnosis of wolf–hirschhorn syndrome: from ultrasound findings, diagnostic technology to genetic counseling. Archives of Gynecology and Obstetrics, 298:289-295, May 2018. URL: https://doi.org/10.1007/s00404-018-4798-1, doi:10.1007/s00404-018-4798-1. This article has 36 citations and is from a peer-reviewed journal.

17. (luo2023prenataldiagnosisand pages 2-3): H Luo, R Chang, F Liu, and X Gao. Prenatal diagnosis and molecular cytogenetic analyses of a de novo deletion on chromosome 4p16. 3p15. 33. Unknown journal, 2023.

18. (nevado2020internationalmeetingon pages 4-5): Julián Nevado, Karen S. Ho, Marcella Zollino, Raquel Blanco, César Cobaleda, Christelle Golzio, Isabelle Beaudry‐Bellefeuille, Sarah Berrocoso, Jacobo Limeres, Pilar Barrúz, Candela Serrano‐Martín, Concetta Cafiero, Ignacio Málaga, Giuseppe Marangi, Elena Campos‐Sánchez, Tania Moriyón‐Iglesias, Sorangui Márquez, Leah Markham, Hope Twede, Amanda Lortz, Lenora Olson, Xiaoming Sheng, Cindy Weng, Edward Robert Wassman, Tara Newcomb, Edward Robert Wassman, John C. Carey, Agatino Battaglia, Eduardo López‐Granados, Damien Douglas, and Pablo Lapunzina. International meeting on wolf‐hirschhorn syndrome: update on the nosology and new insights on the pathogenic mechanisms for seizures and growth delay. American Journal of Medical Genetics Part A, 182:257-267, Nov 2020. URL: https://doi.org/10.1002/ajmg.a.61406, doi:10.1002/ajmg.a.61406. This article has 31 citations.

19. (shannon2001anepidemiologicalstudy pages 1-1): N. Shannon, E. Maltby, A. Rigby, and O. Quarrell. An epidemiological study of wolf-hirschhorn syndrome: life expectancy and cause of mortality. Journal of Medical Genetics, 38:674-679, Oct 2001. URL: https://doi.org/10.1136/jmg.38.10.674, doi:10.1136/jmg.38.10.674. This article has 138 citations and is from a domain leading peer-reviewed journal.

20. (nevado2025clinicianbasedfunctionalscoring pages 1-2): Julián Nevado, Raquel Blanco-Lago, Cristina Bel-Fenellós, Adolfo Hernández, María A. Mori-Álvarez, Chantal Biencinto-López, Ignacio Málaga, Harry Pachajoa, Elena Mansilla, Fe A. García-Santiago, Pilar Barrúz, Jair A. Tenorio-Castaño, Yolanda Muñoz-GªPorrero, Isabel Vallcorba, and Pablo Lapunzina. Clinician-based functional scoring and genomic insights for prognostic stratification in wolf–hirschhorn syndrome. Genes, 16:820, Jul 2025. URL: https://doi.org/10.3390/genes16070820, doi:10.3390/genes16070820. This article has 1 citations.

21. (shannon2001anepidemiologicalstudy pages 3-4): N. Shannon, E. Maltby, A. Rigby, and O. Quarrell. An epidemiological study of wolf-hirschhorn syndrome: life expectancy and cause of mortality. Journal of Medical Genetics, 38:674-679, Oct 2001. URL: https://doi.org/10.1136/jmg.38.10.674, doi:10.1136/jmg.38.10.674. This article has 138 citations and is from a domain leading peer-reviewed journal.

22. (shannon2001anepidemiologicalstudy pages 4-5): N. Shannon, E. Maltby, A. Rigby, and O. Quarrell. An epidemiological study of wolf-hirschhorn syndrome: life expectancy and cause of mortality. Journal of Medical Genetics, 38:674-679, Oct 2001. URL: https://doi.org/10.1136/jmg.38.10.674, doi:10.1136/jmg.38.10.674. This article has 138 citations and is from a domain leading peer-reviewed journal.

23. (shannon2001anepidemiologicalstudy pages 6-6): N. Shannon, E. Maltby, A. Rigby, and O. Quarrell. An epidemiological study of wolf-hirschhorn syndrome: life expectancy and cause of mortality. Journal of Medical Genetics, 38:674-679, Oct 2001. URL: https://doi.org/10.1136/jmg.38.10.674, doi:10.1136/jmg.38.10.674. This article has 138 citations and is from a domain leading peer-reviewed journal.

24. (nevado2020internationalmeetingon pages 11-11): Julián Nevado, Karen S. Ho, Marcella Zollino, Raquel Blanco, César Cobaleda, Christelle Golzio, Isabelle Beaudry‐Bellefeuille, Sarah Berrocoso, Jacobo Limeres, Pilar Barrúz, Candela Serrano‐Martín, Concetta Cafiero, Ignacio Málaga, Giuseppe Marangi, Elena Campos‐Sánchez, Tania Moriyón‐Iglesias, Sorangui Márquez, Leah Markham, Hope Twede, Amanda Lortz, Lenora Olson, Xiaoming Sheng, Cindy Weng, Edward Robert Wassman, Tara Newcomb, Edward Robert Wassman, John C. Carey, Agatino Battaglia, Eduardo López‐Granados, Damien Douglas, and Pablo Lapunzina. International meeting on wolf‐hirschhorn syndrome: update on the nosology and new insights on the pathogenic mechanisms for seizures and growth delay. American Journal of Medical Genetics Part A, 182:257-267, Nov 2020. URL: https://doi.org/10.1002/ajmg.a.61406, doi:10.1002/ajmg.a.61406. This article has 31 citations.

25. (osundiji2024afamilialchromosome pages 7-8): Mayowa Azeez Osundiji, Eva Kahn, and Brendan Lanpher. A familial chromosome 4p16.3 terminal microdeletion that does not cause wolf-hirschhorn (4p-) syndrome. Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology, 32 4:13, Nov 2024. URL: https://doi.org/10.1007/s10577-024-09757-9, doi:10.1007/s10577-024-09757-9. This article has 0 citations.

26. (shannon2001anepidemiologicalstudy pages 5-6): N. Shannon, E. Maltby, A. Rigby, and O. Quarrell. An epidemiological study of wolf-hirschhorn syndrome: life expectancy and cause of mortality. Journal of Medical Genetics, 38:674-679, Oct 2001. URL: https://doi.org/10.1136/jmg.38.10.674, doi:10.1136/jmg.38.10.674. This article has 138 citations and is from a domain leading peer-reviewed journal.

27. (blancolago2025epilepsyinwolf–hirschhorn pages 9-11): Raquel Blanco-Lago, Ignacio Málaga, Jair Antonio Tenorio-Castaño, Nelly Álvarez-Álvarez, Pablo Lapunzina, and Julián Nevado. Epilepsy in wolf–hirschhorn syndrome: clinical insights from a pediatric cohort and a review of the literature. Journal of Clinical Medicine, 14:8044, Nov 2025. URL: https://doi.org/10.3390/jcm14228044, doi:10.3390/jcm14228044. This article has 0 citations.

28. (xing2018prenataldiagnosisof pages 3-5): Ya Xing, Jimmy Lloyd Holder, Yong Liu, Meizhen Yuan, Qi Sun, Xiaoxing Qu, Linbei Deng, Jia Zhou, Yingjun Yang, Ming Guo, Sau-Wai Cheung, and Luming Sun. Prenatal diagnosis of wolf–hirschhorn syndrome: from ultrasound findings, diagnostic technology to genetic counseling. Archives of Gynecology and Obstetrics, 298:289-295, May 2018. URL: https://doi.org/10.1007/s00404-018-4798-1, doi:10.1007/s00404-018-4798-1. This article has 36 citations and is from a peer-reviewed journal.

29. (ho2016chromosomalmicroarraytesting media 365127d8): Karen S Ho, Sarah T South, Amanda Lortz, Charles H Hensel, Mallory R Sdano, Rena J Vanzo, Megan M Martin, Andreas Peiffer, Christophe G Lambert, Amy Calhoun, John C Carey, and Agatino Battaglia. Chromosomal microarray testing identifies a 4p terminal region associated with seizures in wolf–hirschhorn syndrome. Journal of Medical Genetics, 53:256-263, Jan 2016. URL: https://doi.org/10.1136/jmedgenet-2015-103626, doi:10.1136/jmedgenet-2015-103626. This article has 59 citations and is from a domain leading peer-reviewed journal.